Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3389404 in Healthy Subjects
NCT02647281Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3389404 in hepatitis B (HBV) (9 arms), sponsored by GSK. Primary endpoints: Adverse Events at 115 days, Laboratory Values of Potential Clinical Importance at 115 days and 4 more. Started Dec 2015; status: completed.
02
Drugs
GSK3389404
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02647281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647281.